Evidence map›Paper›PMID 26702681›Full record

Observational studyIndian heart journal

Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain.

Anjith Vupputuri, Saritha Sekhar, Sajitha Krishnan, K Venugopal, K U Natarajan

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Advances in biomarkers for myocardial injury after non-cardiac surgery.Journal of anesthesia and translational medicine · 2026
    Review
  6. Review
  7. Neutrophil lymphocyte ratio and heart type fatty acid binding protein as a prognostic marker in Myocardial infarction within 48 h of admission.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Observational
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Anjith VupputuriDepartment of Cardiology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham University, India.
Saritha SekharAssociate Professor, Department of Cardiology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham University, Kochi, India.
Sajitha KrishnanProfessor, Department of Biochemistry, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham University, India.
K VenugopalProfessor and Head, Department of Cardiology, Pushpagiri Institute of Medical Sciences, Tiruvalla, India.
K U NatarajanProfessor and Head, Department of Cardiology, Amrita Institute of Medical Sciences and Research, Amrita Vishwa Vidyapeetham University, India. Electronic address: kunatarajan@aims.amrita.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeart-type fatty acid-binding protein (H-FABP) is an emerging biomarker, which was found to be sensitive for the early diagnosis of acute myocardial infarction (AMI). We prospectively investigated the usefulness of H-FABP determination for the evaluation of acute chest pain in patients arriving at the emergency department.

methodsFifty-four patients presenting with acute ischemic chest pain were evaluated. H-FABP was estimated at admission using latex-enhanced immunoturbidimetric assay. Serial cardiac troponin I (cTnI), creatinine kinase-MB (CK-MB) determination, ischemia workup with stress testing, and/or coronary angiogram (CAG) were performed according to standard protocols.

resultsThe sensitivity and specificity of H-FABP was 89.7% and 68%, for cTnI it was 62.1% and 100%, and for CK-MB it was 44.8% and 92%, respectively for diagnosis of AMI. The sensitivity of H-FABP was found to be far superior to initial cTnI and CK-MB, for those seen within 6h (100% vs. 46.1%, 33% respectively). On further evaluation of patients with positive H-FABP and negative cTnI, 71.4% of the patients had significant lesion on CAG, indicating ischemic cause of H-FABP elevation. Six patients with normal cTnI and CK-MB with high H-FABP had ST elevation on subsequent ECGs and were taken for primary angioplasty.

conclusionH-FABP is a highly sensitive biomarker for the early diagnosis of AMI. H-FABP as early marker and cTnI as late marker would be the ideal combination to cover the complete diagnostic window for AMI. Detection of myocardial injury by H-FABP may also be applied in patients with unstable angina. H-FABP can also be used as a marker for early detection of STEMI before the ECG changes become apparent.

Indexed as

Early DiagnosisAcute PainBiomarkersChest PainFatty Acid Binding Protein 3Fatty Acid-Binding ProteinsFemaleFollow-Up StudiesHumansIncidenceIndiaMaleMiddle AgedMyocardial InfarctionProspective StudiesROC CurveBiomarkersFABP3 protein, humanFatty Acid Binding Protein 3Fatty Acid-Binding ProteinsAcute MIBiochemical markerChest painHeart-type fatty acid-binding protein

Identifiers

PMID26702681
PMCPMC4699962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.